Exam 2 Flashcards
toxicities of sulfa drugs
aplastic anemia hypersensitivity Stevens Johnson Syndrome photosensitivity kernicterus
contraindications for sulfa drugs
near term pregnant women
nursing, premature, or jaundice infants
< 2 months old
sulfasalazine MOA and use
prodrug, metabolite mesalamine is anti-inflammatory
used for Crohn’s, ulcerative colitis, RA
1st DOC for UTI
Bactrim
MOA for Bactrim
sulfamethoxazole: compete with PABA in bacterial cell folic acid synthesis
trimethoprim: prevents conversion of DHF to THF for purine synthesis
spectrum for Bactrim
G+ and G-
relationship of trimethoprim and sulfamethoxazole
synergistic
use of silver sulfaziadine
topical for burns
Bactrim: cidal or static?
bacteriostatic, except it is bactericidal in the urinary tract
MOA of daptomycin
rapidly depolarizes membrane which eventually leads to cell death
spectrum of daptomycin
cidal, G+ (MRSA, MSSA)
route of administration for daptomycin
IV
MOA of mupirocin
inhibit tRNA synthetase of isoleucine, inhibits protein and RNA synthesis
route of administration for mupirocin
topical
skin: impetigo
nares: MRSA
spectrum of mupirocin
G+ and G-, bacteriostatic at low concentrations and bactericidal at high concentrations
MOA for polymixin B and E
binds to lipid A, increases permeability which results in loss of metabolites
spectrum of polymixin B and E
G-
route of administration for polymixin B and E
topical (nephrotoxic), used in combination with neomycin and bacitracin
1st gen cephalosporins
Cephalexin (oral), Cefazolin (IV/IM)
2nd gen cephalosporins
Cefuroxime (IV/IM), Cefprozil (oral), Cefaclor (oral)
3rd gen cephalosporins
Ceftriaxone, Cefixime (oral), Ceftazidime, Cefotaxime
-all others are IV/IM
4th gen cephalosporins
Cefepime (IV)
“5th” gen cephalosporins
Ceftaroline (IV)
DOC for surgery prophylaxis
Cefazolin (IV/IM)
DOC for N. Gonnorhea
Ceftriaxone (IV/IM)
What advantage does cephalosporins have over penicillins?
They have a 7 methyl group that makes them more resistant to penicillinase
MOA of cephalosporins
ICWS, b-lactam
spectrum for 1st gen cephalosporins
good G+, relatively moderate G-, MSSA
spectrum for 2nd gen cephalosporins
lower G+, more G- (E.coli, Klebsiella, Proteus)
3rd gen cephalosporin for Pseudomoas
ceftazidime + aminnoglycoside
spectrum for 3rd gen cephalosporins
less G+, pseduomonas, enterobacteriaceae
contraindications for 3rd gen cephalosporins
neonates due to bilirubin displacement
spectrum for 4th gen cephalosporins
comparable to 3rd gen with more G+ coverage + MSSA
spectrum for 5th gen cephalosporins
G+ and G-, MRSA, VRSA, CABP
NO PSEUDOMONAS ACTIVITY
DOC for E. Coli, Proteus, Klebsiella
1st or 2nd gen cephalosporins
DOC for late stage Borrelia Burgdorferi
Ceftriaxone
Toxicity of cephalosporins
superinfection diarrhea disulfram like reaction allergy (10% cross reaction with pen allergy) dose dependent renal tubular necrosis
MOA for Aztreonam
a b-lactam, ICWS, PBP, cidal
spectrum for aztreonam
G- only
route of administration for azetronam
parenteral
list carbapenems
imipenem (+ cilastatin), meropenem, ertapenem
route for imipenem and meropenem
IV
spectrum for impienem and meropenem
G+, G-, Anaerobes
BROAD SPECTRUM
toxicity of imipenem
can cause seizures, so patients with past history, impaired kidney function, CNS deficits should avoid
DOC for B-lactam producing enterobacter infection
imipenem or meropenem
spectrum for ertapenem
G+, G-, anaerobic, particular enterobacteriaceae
do not use for pseudomonas
route for ertapenem
IV or IM
MOA for vancomycin
cidal, ICWS, prevents transpeptidation of chain by binding to the D-alanine site
Resistance MOA for vancomycin
bacteria mutates d-ala to d-lactate so drug cannot bind
Adverse affects of vancomycin
ototoxicity
nephrotoxicity
red man syndrome (not a hypersensitivity)
route for vancomycin
ORAL
spectrum for vancomycin
G+, MRSA, G+ infections not responding to penicillin
DOC for C. Diff
Vancomycin
MOA of fosfomycin
inhibits cell wall synthesis at one of the first steps in the peptidoglycan pathway
spectrum of fosfomycin
G+ and G-
MOA of bacitracin
interferes with the final dephosphorylation step, NAG-NAM cannot get transported across the membrane
route for bacitracin
parenteral (rarely nephrotoxic) and topical